title: Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel.
abstract: METHODS
  Cetuximab therapy results strongly active in advanced cutaneous squamous cell carcinoma (cSCC). A patient affected by a rapidly progressing, already irradiated and cisplatin-refractory cSCC, with lung, pleura and thoracic lymph nodes metastasis, was treated with weekly cetuximab and paclitaxel.
  
  
  RESULTS
  Treatment was well tolerated and a partial response was obtained after four months of cetuximab plus paclitaxel therapy. Then we continued maintenance cetuximab for another seven months with tumor shrinkage until complete response, maintained after six months.
  
  
  CONCLUSIONS
  Cetuximab was safely associated with paclitaxel, obtaining a rapid tumor response in cisplatin-refractory metastatic cSCC. Single-agent cetuximab maintenance sustained tumor shrinkage until complete response.
authors.affiliation: Medical Oncology 1 Division, San Giovanni Battista Hospital, Corso Bramante 88,Turin, Italy. caterinamecca@yahoo.it
authors.forename: Caterina
authors.initials: C
authors.lastname: Mecca
authors.forename: Agostino
authors.initials: A
authors.lastname: Ponzetti
authors.forename: Virginia
authors.initials: V
authors.lastname: Caliendo
authors.forename: Libero
authors.initials: L
authors.lastname: Ciuffreda
authors.forename: Patrizia
authors.initials: P
authors.lastname: Lista
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D000068818:Cetuximab; D006801:Humans; D060828:Induction Chemotherapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000556:secondary; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D000068818:Cetuximab